蒋亭亭,梅 峰

2型糖尿病是全球慢性肾脏病(chronic kidney disease，CKD)的首要病因，而糖尿病肾脏疾病（diabetic kidney disease，DKD）是糖尿病主要的微血管并发症，同时也是引起终末期肾脏病（ESKD）的主要原因。然而，尽管使用血管紧张素转换酶抑制剂(ACEIs)和血管紧张素受体拮抗剂(ARBs)控制血压，以及优化血糖控制，但降低进展为终末期肾病（ESKD）的风险仍然不理想。非奈利酮是一种新型的、选择性的非甾体MR拮抗剂(MRA )[1,2],能均衡分布于肾脏和心脏，能同时兼顾心肾双重获益。

2型糖尿病；慢性肾脏病；非奈利酮

[1] Grune J,Benz V,Brix S,等.Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy[J].Journal of Cardiovascular Pharmacology,2016,67(5):402–411. [2] Bramlage P,Swift S L,Thoenes M,等.Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease[J].European Journal of Heart Failure,2016,18(1):28–37. [3] Li H,Lu W,Wang A,等.Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017:Estimates from Global Burden of Disease 2017[J].Journal of Diabetes Investigation,2021,12(3):346–356. [4] Li Y,Teng D,Shi X,等.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J].BMJ,2020:m997. [5] Lee J F,Berzan E,Sridhar V S,等.Cardiorenal Protection in Diabetic Kidney Disease[J].Endocrinology and Metabolism(Seoul,Korea),2021,36(2):256–269. [6] Fang M,Wang D,Coresh J,等.Trends in Diabetes Treatment and Control in U.S.Adults,1999-2018[J].The New England Journal of Medicine,2021,384(23):2219–2228. [7] Bauersachs J,Jaisser F,Toto R.Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases[J].Hypertension(Dallas,Tex.:1979),2015,65(2):257–263. [8] Barrera-Chimal J,Bonnard B,Jaisser F.Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases[J].Annual Review of Physiology,2022,84:585–610. [9] 新型盐皮质激素受体拮抗剂的临床应用.pdf[J]. [10] Epstein M.Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury:From Hans Selye to the Present[J].American Journal of Nephrology,2021,52(3):209–216. [11] Epstein M.A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021:A Paradigm Shift[J].Diabetes Therapy:Research,Treatment and Education of Diabetes and Related Disorders,2022,13(4):583–588. [12] Erraez S,López-Mesa M,Gómez-Fernández P.Mineralcorticoid receptor blockers in chronic kidney disease[J].Nefrologia,2021,41(3):258–275. [13] Bomback A S.Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease:Efficacy and Safety[J].Blood Purification,2016,41(1–3):166–170. [14] Rossi G P,Belfiore A,Bernini G,等.Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients[J].The Journal of Clinical Endocrinology and Metabolism,2008,93(7):2566–2571. [15] Ruggenenti P,Cravedi P,Remuzzi G.The RAAS in the pathogenesis and treatment of diabetic nephropathy[J].Nature Reviews.Nephrology,2010,6(6):319–330. [16] Erraez S,López-Mesa M,Gómez-Fernández P.Mineralcorticoid receptor blockers in chronic kidney disease[J].Nefrologia,2021,41(3):258–275. [17] Chaudhuri A,Ghanim H,Arora P.Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease:A review of pathophysiology,mechanisms,and evidence from recent trials[J].Diabetes,Obesity&Metabolism,2022,24(3):365–376. [18] Kanbay M,Demiray A,Afsar B,等.Role of Klotho in the Development of Essential Hypertension[J].Hypertension(Dallas,Tex.:1979),2021,77(3):740–750. [19] Ruiz-Ortega M,Rayego-Mateos S,Lamas S,等.Targeting the progression of chronic kidney disease[J].Nature Reviews.Nephrology,2020,16(5):269–288. [20] Agarwal R,Kolkhof P,Bakris G,等.Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine[J].European Heart Journal,2021,42(2):152–161. [21] Agarwal R,Anker S D,Bakris G,等.Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes:the role of finerenone[J].Nephrology,Dialysis,Transplantation:Official Publication of the European Dialysis and Transplant Association-European Renal Association,2022,37(6):1014–1023. [22] Epstein M,Williams G H,Weinberger M,等.Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes[J].Clinical journal of the American Society of Nephrology:CJASN,2006,1(5):940–951. [23] Chrysostomou A,Pedagogos E,MacGregor L,等.Double-blind,placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy,with or without an angiotensin II receptor blocker[J].Clinical journal of the American Society of Nephrology:CJASN,2006,1(2):256–262. [24] Amazit L,Le Billan F,Kolkhof P,等.Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1[J].The Journal of Biological Chemistry,2015,290(36):21876–21889. [25] Le Billan F,Perrot J,Carceller E,等.Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells[J].FASEB journal:official publication of the Federation of American Societies for Experimental Biology,2021,35(2):e21314. [26] Kolkhof P,Delbeck M,Kretschmer A,等.Finerenone,a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury[J].Journal of Cardiovascular Pharmacology,2014,64(1):69–78. [27] González-Blázquez R,Somoza B,Gil-Ortega M,等.Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress[J].Frontiers in Pharmacology,2018,9:1131. [28] Orena S,Maurer T S,She L,等.PF-03882845,a non-steroidal mineralocorticoid receptor antagonist,prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy[J].Frontiers in Pharmacology,2013,4:115. [29] Pitt B,Kober L,Ponikowski P,等.Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease:a randomized,double-blind trial[J].European Heart Journal,2013,34(31):2453–2463. [30] Filippatos G,Anker S D,Böhm M,等.A randomized controlled study of finerenone vs.eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease[J].European Heart Journal,2016,37(27):2105–2114. [31] Bakris G L,Agarwal R,Chan J C,等.Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy:A Randomized Clinical Trial[J].JAMA,2015,314(9):884–894. [32] Dojki F K,Bakris G.Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease[J].Current Opinion in Nephrology and Hypertension,2017,26(5):368–374. [33] Górriz J L,González-Juanatey J R,Facila L,等.Finerenona:completando el abordaje del paciente con enfermedad renal y diabetes[J].Nefrología,2023,43(4):386–398. [34] Bakris G L,Agarwal R,Anker S D,等.Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes[J].The New England Journal of Medicine,2020,383(23):2219–2229. [35] Pitt B,Filippatos G,Agarwal R,等.Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes[J].The New England Journal of Medicine,2021,385(24):2252–2263. [36] Agarwal R,Filippatos G,Pitt B,等.Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease:the FIDELITY pooled analysis[J].European Heart Journal,2022,43(6):474–484.

点击下载PDF